Related Experiment Video

Updated: May 10, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Pharmacokinetic considerations for antithrombotic therapies in stroke

Stavros Apostolakis1, Gregory Yh Lip, Eduard Shantsila

  • 1University of Birmingham, Centre for Cardiovascular Sciences, City Hospital , Birmingham , UK +44 121 507 5086 ; +44 121 544 4083 ; s.apostolakis@bham.ac.uk.

Expert Opinion on Drug Metabolism & Toxicology
|June 12, 2013
PubMed

Insights

Antithrombotic therapies, including antiplatelets and anticoagulants, are crucial for preventing recurrent ischemic strokes. While antiplatelets are key for secondary prevention, new oral anticoagulants show promise for atrial fibrillation patients.

Area of Science:

  • Neurology
  • Pharmacology
  • Cardiology

Background:

  • Stroke recurrence, morbidity, and mortality are significant global health concerns.
  • Antithrombotic therapy is fundamental for secondary prevention of ischemic stroke.

Purpose of the Study:

  • To review current antithrombotic therapies for ischemic stroke management.
  • To examine pharmacokinetic properties and their clinical impact.
  • To cover antiplatelet and anticoagulant uses in primary and secondary stroke prevention.

Main Methods:

  • Literature review of antithrombotic therapies.
  • Focus on pharmacokinetic properties and clinical utility.
  • Inclusion of antiplatelet and anticoagulant agents.

Main Results:

  • Aspirin is established in early stroke management and antiplatelet drugs (aspirin, aspirin/dipyridamole, clopidogrel) are cornerstones for secondary prevention.
  • Limited data exists for novel antiplatelet agents in stroke.
  • Anticoagulation showed no early benefit in acute ischemic stroke; long-term Vitamin K antagonists benefit atrial fibrillation patients.
  • New oral anticoagulants demonstrate comparable efficacy to Vitamin K antagonists in preventing stroke in atrial fibrillation.

Conclusions:

  • Antiplatelet agents are vital for secondary stroke prevention.
  • Novel antiplatelet and anticoagulant therapies require further investigation for stroke management.
  • Long-term anticoagulation is beneficial for specific patient groups, with newer agents offering comparable efficacy.
Abstract

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...